Explore our sister journals here.

Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Citing this Article

Right click to copy or hit: ctrl+c (cmd+c on mac)

Published on 15.12.17 in Vol 3, No 4 (2017): Oct-Dec

This paper is in the following e-collection/theme issue:

Works citing "Viral Hepatitis Strategic Information to Achieve Elimination by 2030: Key Elements for HIV Program Managers"

Yvan Hutin, Daniel Low-Beer, Isabel Bergeri, Sarah Hess, Jesus Maria Garcia-Calleja, Chika Hayashi, Antons Mozalevskis, Annemarie Rinder Stengaard, Keith Sabin, Hande Harmanci, Marc Bulterys

JMIR Public Health Surveill 2017 (Dec 15); 3(4):e91 

According to Crossref, the following articles are citing this article (DOI 10.2196/publichealth.7370):

(note that this is only a small subset of citations)

  1. Nguyen MH, Wong G, Gane E, Kao J, Dusheiko G. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clinical Microbiology Reviews 2020;33(2)
    CrossRef
  2. Behzadifar M, Gorji HA, Rezapour A, Bragazzi NL. The hepatitis C infection in Iran: a policy analysis of agenda-setting using Kingdon’s multiple streams framework. Health Research Policy and Systems 2019;17(1)
    CrossRef
  3. Reiser M, Wiebner B, Hirsch J. Neural-network analysis of socio-medical data to identify predictors of undiagnosed hepatitis C virus infections in Germany (DETECT). Journal of Translational Medicine 2019;17(1)
    CrossRef
  4. Cheng C, Feng C, Chua CS. Help-Seeking Experiences of Hepatitis B Patients in Transnational Medical Care: The Solution to Health Inequality Is Social Mobility. Healthcare 2019;7(4):125
    CrossRef
  5. Mårdh O, Quinten C, Amato-Gauci AJ, Duffell E. Mortality from liver diseases attributable to hepatitis B and C in the EU/EEA – descriptive analysis and estimation of 2015 baseline. Infectious Diseases 2020;52(9):625
    CrossRef
  6. Rice B, Sanchez T, Baral S, Mee P, Sabin K, Garcia-Calleja JM, Hargreaves J. Know Your Epidemic, Strengthen Your Response: Developing a New HIV Surveillance Architecture to Guide HIV Resource Allocation and Target Decisions. JMIR Public Health and Surveillance 2018;4(1):e18
    CrossRef
  7. Pedrana A, Howell J, Scott N, Schroeder S, Kuschel C, Lazarus JV, Atun R, Baptista-Leite R, 't Hoen E, Hutchinson SJ, Aufegger L, Peck R, Sohn AH, Swan T, Thursz M, Lesi O, Sharma M, Thwaites J, Wilson DP, Hellard M. Global hepatitis C elimination: an investment framework. The Lancet Gastroenterology & Hepatology 2020;5(10):927
    CrossRef
  8. Behzadifar M, Gorji HA, Rezapour A, Bragazzi NL. Comparison of prevention, screening and treatment of hepatitis C in Iran, Egypt and Georgia. Journal of Virus Eradication 2019;5(2):116
    CrossRef
  9. Applegate TL, Fajardo E, Sacks JA. Hepatitis C Virus Diagnosis and the Holy Grail. Infectious Disease Clinics of North America 2018;32(2):425
    CrossRef
  10. Jefferies M, Rauff B, Rashid H, Lam T, Rafiq S. Update on global epidemiology of viral hepatitis and preventive strategies. World Journal of Clinical Cases 2018;6(13):589
    CrossRef
  11. Howell J, Pedrana A, Schroeder SE, Scott N, Aufegger L, Atun R, Baptista-Leite R, Hirnschall G, ‘t Hoen E, Hutchinson SJ, Lazarus JV, Olufunmilayo L, Peck R, Sharma M, Sohn AH, Thompson A, Thursz M, Wilson D, Hellard M. A global investment framework for the elimination of hepatitis B. Journal of Hepatology 2021;74(3):535
    CrossRef
  12. Al Awaidy ST, Ezzikouri S. Moving towards hepatitis B elimination in Gulf Health Council states: From commitment to action. Journal of Infection and Public Health 2020;13(2):221
    CrossRef
  13. Li M, Wang Z, Zhang L, Zheng H, Zhou M, Liu D. Burden of viral hepatitis caused by specific aetiologies in China, 1990–2016: findings from the GBD 2016. BMC Public Health 2020;20(1)
    CrossRef
  14. Duffell E, Cortez‐Pinto H, Simonova M, Dalgard O, Dahl EH, de Martel C, Mozalevskis A, Buti M, Pavlova S, Hadzhilova T, Simões C, Katzarov K, Mardh O. Estimating the attributable fraction of cirrhosis and hepatocellular carcinoma due to hepatitis B and C. Journal of Viral Hepatitis 2021;28(8):1177
    CrossRef
  15. Alberts CJ, Clifford GM, Georges D, Negro F, Lesi OA, Hutin YJ, de Martel C. Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review. The Lancet Gastroenterology & Hepatology 2022;7(8):724
    CrossRef
  16. Flores E, Howell J. Bridging the gap to achieve viral hepatitis mortality targets. The Lancet Gastroenterology & Hepatology 2022;7(8):691
    CrossRef
  17. Kalluri HV, Oberoi RK, Chen Q, Jiang Q, Asatryan A, Alami NN, Yu C, Liu W. Pharmacokinetics, Tolerability, and Safety of Glecaprevir/Pibrentasvir Co‐formulated Bilayer Tablet Following Repeated Administration in Healthy Chinese Adults. Clinical Pharmacology in Drug Development 2023;12(10):945
    CrossRef
  18. Howell J, Seaman C, Wallace J, Xiao Y, Scott N, Davies J, de Santis T, Adda D, El-Sayed M, Feld JJ, Gane E, Lacombe K, Lesi O, Mohamed R, Silva M, Tu T, Revill P, Hellard ME. Pathway to global elimination of hepatitis B: HBV cure is just the first step. Hepatology 2023;78(3):976
    CrossRef
  19. Holt B, Fernandez M, Nguyen D, Delima D, Duy LD, Gaspar M, Hamoy G, Le BN, Llevado J, Manlutac JMD, Mendoza J, Mercado T, Nguyen H, Nguyen HT, Ong J, Rombaoa MC, Florendo J, Dela Cruz JM, Pham T, Thai PN, Truong PX, Pollack T, Duong D. Embedding viral hepatitis into primary healthcare: results of a strategic landscape analysis in Vietnam and the Philippines. The Lancet Regional Health - Western Pacific 2024;44:100990
    CrossRef

According to Crossref, the following books are citing this article (DOI 10.2196/publichealth.7370):

  1. Nath Chatterjee A, Al Basir F. Mathematical Analysis of Infectious Diseases. 2022. :231
    CrossRef
  2. Ward JW, Wanlapakorn N, Poovorawan Y, Shouval D. Plotkin's Vaccines. 2023. :389
    CrossRef